Series A momentum POC Pharma recently closed a $10.3M Series A led by Alven with participation from Picus Capital, FEBE Ventures, and FJ Labs, signaling strong investor confidence and potential for scaled customer acquisition and enterprise partnerships in emerging markets.

Emerging markets focus Positioned as a data solutions provider for pharma stakeholders in Emerging Markets, there is a clear opportunity to target regional pharmaceutical companies, contract research organizations, and regulatory bodies seeking cost-effective data infrastructure and analytics.

SaaS B2B model As a B2B service SaaS with a scalable platform, there are upsell opportunities around expanded data solutions, analytics modules, and customized deployments for larger pharma manufacturers and distributors looking to accelerate growth.

Tech stack leverage With cloud-based infrastructure (AWS, Google Cloud), containers (Docker), and data tools (PostgreSQL), there is potential to pitch integrated analytics, data warehousing, and security enhancements to prospects prioritizing reliability, compliance, and performance at scale.

Strategic partnership seeds Active investors and a multi-party funding backdrop suggest openness to strategic partnerships, co-sell arrangements, and pilot programs with larger CROs or regional pharma networks aiming to expand footprints in Southeast Asia and beyond.